U.S. Markets closed

GW Pharmaceuticals plc (GWPH)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
106.13-1.89 (-1.75%)
At close: 4:00PM EDT
People also watch
INSYCARACANNTRTCMJNA
  • https://uk.news.yahoo.com/epilepsy-marijuana-cannabis-drug-reduces-210002679.html
    Good news for GW. BUT/
    Be very careful investing in GW. if GW fail again for a 2nd time getting a medicine FDA approved, i expect late this year or next year GW will again create a new batch of shares via a new share offering which debases original share holders.
    GW utilise this trick very often as GW have no revenue other than a few nickel & dimes from Sativex.
    However, insys 2018 will have their own working synthetic Epidiolex clone which i expect will get FDA approval which will cause GW substantial losses as insys will create their Cannabidiol Oral Solution much cheaper & being synthetic will be able to knock out the pills by the billions.
    YOU'VE ALL BEEN WARNED, About me, i held GW for 12 years & dumped the lot way above $120. Bought into a better MJ company which generates substantial revenue. No guesses for what MJ company im holding!

    Epilepsy and Marijuana: Cannabis Drug Reduces Dravet Syndrome Seizures in Large-Scale Clinical Trial
    A marijuana-based drug has shown promising results as a treatment for a rare and deadly form of epilepsy in its first large-scale clinical trial. Dravet syndrome normally appears in the first year of life. Unlike other forms of epilepsy, seizures c
    uk.news.yahoo.com
  • today's news on INSYS is starting to set in. Reality will come when their drugs are approved instead of GW's. That make 2 in the US for INSYS while GW = 0.
  • Analyst: GW Pharma Has Started Laying The Groundwork For Taking Epidiolex To Market A $208 Price target
    Elemer Piros of Cantor Fitzgerald maintained an Overweight rating and $208 price target on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) after the developer of cannbinoid products reported its fiscal second-quarter results.

    Piros' main takeaway from the report and conference call is that GW Pharmaceuticals is on track to file its NDA (new drug application) for its Epidiolex therapy in mid-2017. The company also expects to submit its European filing in the bottom half of 2017.

    Piros highlighted two key portions in progress to support the Epidiolex:

    An integrated safety analysis of over 1,500 patients from clinical studies and the expanded access program.
    Manufacturing data from the manufacturing processes, including scaled materials.
    The two elements will likely be the only determining factors relating to the timing of the NDA submission, but is nevertheless expected by the middle of the year.

    See Also: Cannabis Industry Has Already Raised Over $730 Million In 2017

    Laying The Groundwork

    Piros noted that a subsidiary of GW Pharmaceutical called Greenwich Biosciences is already working on a pre-commercial strategy to expand its workforce in advance of the launch of Epidiolex.

    The company laid out its vision for a sales force of up to 60 representatives, which can reach up to five thousand targeted U.S. physicians. In addition, the company also began engaging payors on awareness of patient need for Epidiolex and its pricing.

    "We believe these efforts will set a meaningful foundation for Epidiolex's commercial launch, which we estimate will initiate in 2018," Piros wrote.

    The analyst noted the company expects a Phase 2 readout from its CBDV program involving adult seizure patients in the fourth quarter of 2017.

    Bottom line, the analyst is "encouraged" by the company's progress in the most recent quarter.

    Latest Ratings for GWPH DateFirmActionFromTo

    Oct 2016Leerink SwannAssumesOutperform Sep 2016Morgan StanleyMaintainsOverweight Sep 2016Cantor FitzgeraldMaintainsBuy

    View More Analyst Ratings for GWPH
    View the Latest Analyst Ratings

    © 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
    Benzinga
  • Hey guys this is the start, we are heading to $200 fast!! Only 24 million shares outstanding and the first large pharma company to deliver a cannibas derived cannibas drug- drugs. Well I am happy patients that need this treatment will finally get some relief. Epilepsy and siezures are tough and any way to minimize the pain experienced is welcomed, thank you GWPH!!!
  • Folks it is time fast approaching!~ All of the controversy of Opiod death tolls rising directly breath excitement and enrgy for the likes of GW Pharmaceuitcals. I truly see GWPH as the Google of the cannnibas medicinal space. more effective , longer lasting pain pill medication that is far less addictive, if addictive at all. I was in a near death car accident in December of 2003. My car flipped front to back I was told 8 times when my Yukon and I lost control after being struck by a motorist in a T-Bone collision where my car was struck in the rear 1/4 and bumper on the passenger side. I was ejected to the snow covered ground, 3 inches, and founs face down 100 yards from where my Yukon came to rest in the median on Capitol dr by the Pewaukee/Brookfield area. I was traveling 55 mph. The other driver pulled out without looking, struck my vehicle and he pulled to the middle holding area that allows him to cross Capitol dr and head west towards Madison etc. By the grace of God there happened to be a doctor that witnessed the accident. The driver at fault pulled his car to the side and went to look for me in the Yukon. The doctor saw where I landed on the ground and found me face down without a pulse and I was not breathing. Im not sure how long I was "out"? The doctor flipped me over and raised my left arm and my reflexes kicked in and I came back! I was induced in a coma for 7 days on life support and breathing tubes etc. Major concussion, broken bones in my left arm, a smashed pelvic bone and a puntured lung. I lost my memory for about 2 months. I lived in a hospital and rehab center for 3 months without a clue as to what happened. My High School buddies, John,Tom , Troy and Chris were standing over me after I came to. I asked what happened and did I hurt anyone. I was the only injured person during the ordeal. I honestly do not believe I would have survived without the pain medications.
    My entire point is that there are plenty of us that need effective long term pain management options. I personally endorse and eagerly await new options that will be brought to the market place by GW Pharmaceuticals. After being in a wheel chair for 3 monthsI am incredibly thankful for the pain medications I received and take to this day. Aside from the broken bones and punctured lung and stretched Ulna nerve ( my hand was lifeless for 3 months), I have severe neurapathy in my legs and arms. From the knees to and wrapped around my feet, to my elbows wrapped around my hands. I am anxious to try the innovations that GW Pharemaceuiticals will bring to the market as a new option to combat the horrible effects of a car accident! THE ONLY remarkable thing that came from my accident, aside for being allowed to live another day, is that my first born Alex Joseph was born a few weeks after my accident. I was transported to his hospital where my wife and I brought a bright new human being into this world. The nurses brought Alex to see me just after he was bon in the operating room. I said " Alex do you remember me"? As the nurse held him for a moment, he stopped crying immediately and looked into my eyes. Well that was a chapter to an ongoing saga. I am trying to illustrate the need for long term pain medications that help to allow me to get by daily. Peace ;)
  • Old News - The only reason that GW pushed this to the press was to compete with Insys Therapeutics, Inc. announcement of the FDA final product label for Syndros. INSY will beat GW to the market with their products. GW is going to hit a brick wall at the FDA as Trump/Sessions flex their nationalistic/anti-marijuana co-agenda (GW is a foreign company). Insy's domestic synthetic cannabinoids will kill GW. Notice that the AH pop fizzled. Smart money is looking for an exit ramp above $100, those holding out for $110 will get burned.
  • Today may have been the last time for making $ here. Has dropped a lot of that run already.
  • http://uk.businessinsider.com/marijuana-epilepsy-drug-2017-5
    Just to prove to GW longs im not a GW basher.
    For over a decade GW was my little baby, now iv moved on.
    But be VERY careful GW longs, insys is right behind GW with their cheaper to create Cannabidiol Oral Solution which is effectively the same as Epidiolex®.
    GW British
    INSY American
    Will the FDA drag their heels over Epidiolex approval?

    A powerful drug derived from marijuana is on the cusp of federal approval
    The drug, created by GW Pharma, appears to reduce seizures in two severe forms of epilepsy. Its active ingredient is the marijuana compound cannabidiol, or...
    uk.businessinsider.com
  • Sell now and get some relief going into the weekend
  • I have watched this company and waited for the price to get under $110 as it goes over this time I don't see it coming back. I said this is the GOOGLE of the drug space and I whole heartedly believe it. This is the only Medical development Marijuana stocks Jim Cramer is endorsing, sees a bright future for GWPH and I do too! Maybe next time I post it will be nearing $200 because I am holding my for the long term now
  • Get read to sick in the fork
  • GWPH with $400 mil in cash and NO debt to launch a pill for Epilepsy later this year early next. Cramer touts as the only REAL cannibas co that is actually producing and soon to be selling this drug. They hired a sales team to launch here is the US and have partnerships with Bayer and Astra Z for Europe!!
  • nice piece on cbd/epidolix on CBS news saturday
  • I think GWPH might have reached its upward limit and that a pullback may be possible. the other week awesomeS-TOCKS alerted this company i think. google them .
  • people get a ticket on the INSY train while you still can.
  • I still don't know why the company is planning to move to Ireland...when they're business was doing so good. sad thread of decisions by upper management. how to see. new CEO soon.
  • Did you see INSYS approval today? Another cash generating cow about to start. And where are the GW approvals? Overseas not is US. Time to drop this POS.
  • Now Bristol-Myers is moving ahead of GWPH
  • Bought more at $102.2, this is the first and ONLY company that will gain FDA approval in this space for a while which will help it gain an edge over the rest, that's why Bayer is all over it with Europe. This is the Google in the drug sector and an out of the park home run in the making. Get ready to soar, I have friends (Doctors) in the Pharmacology development teams that were trained at UW Madison and received their doctorates in Pharmacology and have been in the space for 18 plus years. It's going to move strong SOON, mark my words!! I buy more as I rotate from solid trades in the Chip space, may hold onto some of those to become the next Nvidia, I have 3-4 co's that I really like there too!!!!!!!!!!!! For now this is a steal that I have been waiting for the price to come down closer to 1 hundo as I am loading my ship!!
  • Bought more GWPH @105 the day it went to $101 , even put a lil margin money up, by next year I will be glad I did , Im in it long term and the Epidiolex drug ,I hope it makes 2-3 Million ! The pipeline here is deep, more drugs to come and GWPH is Global .... beside this stock I lean on the Canadian Big 3 of TWMJF, APHQF, ACBFF .... they are overvalued but in time they have football fields of MJ that will have lines of customers when Trudeau says "Go" and things turn legal out there ,which they will and there are not giving out more licenses so those are the companies that will sell all of the product !